Opposing results of the monarchE and PALLAS trials investigating the role of adjuvant treatment with the CDK4/6 inhibitors abemaciclib and palbociclib, respectively, in patients with hormone receptor-positive, HER2-negative early stage breast cancer have recently been presented. Herein, potential reasons why these two drugs that have similar efficacy in the metastatic setting have produced disparate results in the adjuvant setting are discussed.

CDK4/6 inhibitors for HR+HER2− early stage breast cancer : When to escalate treatment? / G. Curigliano. - In: NATURE REVIEWS. CLINICAL ONCOLOGY. - ISSN 1759-4774. - 18:2(2021 Feb), pp. 67-68. [10.1038/s41571-020-00453-1]

CDK4/6 inhibitors for HR+HER2− early stage breast cancer : When to escalate treatment?

G. Curigliano
Conceptualization
2021

Abstract

Opposing results of the monarchE and PALLAS trials investigating the role of adjuvant treatment with the CDK4/6 inhibitors abemaciclib and palbociclib, respectively, in patients with hormone receptor-positive, HER2-negative early stage breast cancer have recently been presented. Herein, potential reasons why these two drugs that have similar efficacy in the metastatic setting have produced disparate results in the adjuvant setting are discussed.
Settore MED/06 - Oncologia Medica
24-nov-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
CDK 4-6 Nature 2021.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 682.81 kB
Formato Adobe PDF
682.81 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/825186
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact